Scholar Rock Inc.
Niche modulators target dysregulated growth factors
This article was originally published in Start Up
Executive Summary
Scholar Rock Inc. hope to use novel antibodies, which it calls “niche modulators,” to home in on latent forms of growth factors that get stored as complexes with other proteins in the spaces between cells. The start-up’s focus in on transforming the TGF-beta family of growth factors into highly specific therapeutics.
You may also be interested in...
Janssen Tabs Start-Up Scholar Rock For New Immunology Approach
The J&J subsidiary has signed a deal with Boston-area Scholar Rock to discover new biologics that aim for a more pinpoint solution to inflammatory disease.
Homology Medicines Inc.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.